(PRWEB) June 13, 2012
Parker Waichman LLP, a national law firm dedicated to representing victims injured by defective drugs, has filed 18 lawsuits alleging Bristol-Myers Squibb and Sanofi-Aventis’ Plavix caused gastrointestinal bleeding. The complaints were all filed on May 30th in the Supreme Court of New York, County of New York.
According to the complaints, the Defendants negligently and/or fraudulently represented Plavix to the public as safe and effective for use. The suits allege that Bristol-Myers Squibb and Sanofi-Aventis hid the defects of Plavix at the cost of patient safety. One Plaintiff, a woman from Polk County, Iowa, started taking Plavix in November 2009 and experienced gastrointestinal hemorrhaging in June 2010 (Case No. 1044994). Another Plaintiff, from Butler, Missouri, began taking Plavix in March 2008 (Case No. 1053071). In 2009, she suffered two gastrointestinal hemorrhages, first in June and again in September.
All suits allege an increased risk of heart attack, stroke, blood disorders and excessive bleeding. The complaints also allege severe and permanent injuries, physical impairment and disfigurement, physical pain and suffering, mental pain and suffering, loss of enjoyment of life and past, present and future medical expenses as a direct result of the defective drug.
The U.S. Food and Drug Administration (FDA) approved Plavix (generic: clopidogrel) in 1997 to prevent atherosclerotic events such as heart attacks, stroke and blood clots in high risk patients. According to the complaints, it was the sixth top selling drug in the United States by 2005, with annual sales reaching $3.5 billion dollars. The lawsuits also allege that the Defendants marketed the medication as a superior alternative to Aspirin; consumers were led to believe that it had greater cardiovascular benefits and was easier on the stomach. The complaint alleges these claims to be false.
In 2005, the New England Journal of Medicine published a study comparing the effects of Plavix versus Aspirin and esomeprazole in patients who had ulcer bleeding. Researchers noted U.S. guidelines, which presumed that Plavix was a preferable choice in patients who had major gastrointestinal intolerance of Aspirin. The authors found that their data conflicted with this guideline, with an 8.6 percent of recurrent bleeding in patients taking Plavix versus 0.7 percent among those taking aspirin and esomeprazole. http://www.nejm.org/doi/full/10.1056/NEJMoa042087
Parker Waichman LLP continues to offer free legal consultations to victims of alleged Plavix side effects, including:
If you or a loved experienced serious, life-threatening internal bleeding, heart attacks, strokes, or a blood disorder, and you believe Plavix is to blame, please contact their office by visiting the firm's Plavix side effects page at http://www.yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
For more information regarding Plavix side effects lawsuits and Parker Waichman LLP, please visit: http://www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).
Parker Waichman LLP
Gary Falkowitz, Managing Attorney